The edge of biotech hedge funds: $1,000/hour expert calls and spotting doomed trials
owl_posting · x · 2026-11-21
Works in Progress publishes Abhishaike Mahajan's deep dive into how biotech-focused hedge funds (Baker Brothers, Deerfield, OrbiMed, each managing $15B+) beat the scientists at predicting trial results:
- Trick 1: Many trials are doomed to fail—pharma companies pursue expensive trials for internal incentives despite public data suggesting failure. Funds deploy research teams and AI tools (increasingly LLMs) to spot these before the market.
- Trick 2: Specialist knowledge—funds pay $500–$1,000/hour to interview doctors and trial advisors for non-obvious insights, all legal.
The counterintuitive core: a surprisingly large share of clinical trial outcomes are decently predictable to anyone willing to look.
More from Venture
- AI Agency Operator: Smarter Models Kill Thin Wrappers but Create Massive Demand for Operators — aryanXmahajan · 2026-11-21
- 16-Year-Old Cold-DMs a Founder, Delivers 1M+ Views in 2 Weeks, Lands Growth Role — jia_seed · 2026-11-21
- Morgan Stanley Exercises Full 147M-Share Anthropic Greenshoe as $ANT Slips Below $83 — basedjensen · 2026-11-21
- Worst fundraising advice: valuation isn't ambition — overpricing early can sink startups — arian_ghashghai · 2026-11-21
- Broadcom plunges 9% as Google reportedly cuts 1M AI chips from 2027 plans — PAstynome · 2026-11-21
- Tech stocks bleed: NVDA -6.93%, MU -12%, AMD -11% in AI selloff meme — GaryMarcus · 2026-11-21